OLMA
NASDAQOlema Pharmaceuticals Inc.
Price$10.90-3.17 (-22.49%)
2026-05-212026-08-25
News · 26 weeks62+700%
2026-03-012026-08-23
Mix2490d
- Insider13(54%)
- Other6(25%)
- SEC Filings4(17%)
- Offering1(4%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider O'Byrne Jason3 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Appoints Jason O’Byrne as Chief Financial OfficerSAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. "We are very pleased to welcome Jason to Olema at an important time for the Company," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "As we approach pivotal data from OPERA-01 and prepare for our first potential commercial launch, the breadth and depth of Jason’s expertise in corporate strate
- SECSEC Form 10-Q filed by Olema Pharmaceuticals Inc.10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Reports Second Quarter 2026 Financial and Operating ResultsCompleted enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual MeetingAnnounced a clinical trial collaboration and supply agreement with Bayer to evaluate darolutamide in combination with OP-3136 in metastatic castration-resistant prostate cancerEnded the second quarter with $461.1 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializa
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock, effective as of August 3, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordanc
- INSIDERDirector Harmon Cyrus sold $291,162 worth of shares (25,000 units at $11.65), decreasing direct ownership by 3% to 702,770 units (SEC Form 4)4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 215,800 shares of the Company's common stock, effective as of July 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance
- INSIDERSEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Harmon Cyrus4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Butitta Cynthia M4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Hrustanovic Gorjan4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Clark Ian T4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Larson Yi4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Horning Sandra4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Raman Prakash4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Rappaport Andrew4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Graham G. Walmsley4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wi
- PRLilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
OLMA FAQ
7 questionsWhat does Olema Pharmaceuticals Inc. do?
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema...Where does OLMA stock trade?
Olema Pharmaceuticals Inc. (OLMA) is listed on NASDAQ.What sector and industry is OLMA in?
Olema Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Olema Pharmaceuticals Inc. go public?
Olema Pharmaceuticals Inc. (OLMA) completed its IPO in 2020.What are analysts saying about OLMA?
Olema Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-03-27. Recent price targets range from $2000.00 to $4800.00.What companies are similar to OLMA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OLMA side-by-side with any of them on Quantisnow.How can I track OLMA on Quantisnow?
Quantisnow aggregates Olema Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OLMA to receive live email and push alerts on every new disclosure.